Source: Ypsomed annual + half-year reports (ypsomed.com investor relations; SIX Swiss Exchange filings); Ypsomed Capital Markets Day decks. Ypsomed discloses Delivery Systems and Diabetes Care segment totals but does NOT name pharma customers or split GLP-1 vs other-pharma revenue, so the customer-level breakdown is estimate-driven and inferred from company commentary plus analyst attribution; the Delivery Systems component sums and the Diabetes Care line match the reported segment totals (Delivery Systems 385.2 FY2023/24, 502.3 FY2024/25; Diabetes Care 151.0 / 236.9). Earlier years are on the older pre-restatement basis and are approximate.

Source: Ypsomed annual + half-year reports (ypsomed.com investor relations; SIX Swiss Exchange filings; YPSN.SW); fiscal year ends March 31; segment table disclosed in annual-report MD&A. FY2023/24 and FY2024/25 figures are the reported continued-operations numbers (Delivery Systems 385.2 / 502.3; Diabetes Care 151.0 / 236.9). Earlier years predate Ypsomed's continued-operations restatement (divestiture of parts of the diabetes business) and are shown on the older reporting basis, so they are approximate and not directly comparable.

Source: Ypsomed FY 2025/26 ad-hoc: Delivery Systems CHF 601.5 million versus CHF 502.3 million, about +20%. https://www.ypsomed.com/en/investors/ad-hoc-announcements/ad-hoc-detail-page/ypsomed-grows-20-in-core-business-and-wins-record-number-of-customer-projects.

Source: Ypsomed FY 2025/26 ad-hoc: project business CHF 85.7 million versus CHF 87.5 million, excluding capacity-reservation fees. https://www.ypsomed.com/en/investors/ad-hoc-announcements/ad-hoc-detail-page/ypsomed-grows-20-in-core-business-and-wins-record-number-of-customer-projects.